News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Forest Laboratories, Inc. (FRX) Announces Settlement of BYSTOLIC® Patent Litigation


11/7/2013 11:00:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd. (collectively, "Forest") announced today that they have entered into a settlement agreement with Actavis, Inc. and related companies and subsidiaries thereof, in patent infringement litigation brought by Forest in response to Actavis’s abbreviated new drug application ("ANDA") seeking approval to market generic versions of Forest's BYSTOLIC® (nebivolol) tablets. This settlement agreement is with the last of the remaining defendants in this patent infringement litigation.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES